Immuno-PET may be performed in patients with MM treated with daratumumab using 89Zr-isatuximab because the epitope of isatuximab does not overlap with the binding site of the CD38 molecule of daratumumab. This evidence concerns the gene CD38 and Miyoshi myopathy.